April 19, 2015New England Journal of Medicine5,924 citationsOpen Access
Pembrolizumab versus Ipilimumab in Advanced Melanoma
View Full Paper
Key Points
- Pembrolizumab prolonged progression-free survival and overall survival compared with ipilimumab in patients with advanced melanoma.
- The anti-PD-1 antibody pembrolizumab also demonstrated less high-grade toxicity than ipilimumab during treatment for advanced melanoma.
- Randomized trial KEYNOTE-006 (NCT01866319) supports pembrolizumab over ipilimumab to improve overall survival in advanced melanoma cases.
Abstract
The anti-PD-1 antibody pembrolizumab prolonged progression-free survival and overall survival and had less high-grade toxicity than did ipilimumab in patients with advanced melanoma. (Funded by Merck Sharp KEYNOTE-006 ClinicalTrials.gov number, NCT01866319.).
Cite This Study
Robert et al. (2015) studied this question.